Contraceptive Technology Update – October 1, 2009
October 1, 2009
View Archives Issues
-
Sterilization update: Two options now approved as transcervical procedures
Women who want a permanent form of birth control now have a new option. The Food and Drug Administration (FDA) has approved the Adiana permanent contraception system, manufactured by Hologic of Bedford, MA. -
Identify women at risk of weight gain with DMPA
Findings from new research may aid clinicians in identifying women who are likely to gain weight while using depot medroxyprogesterone acetate (DMPA, Depo Provera). Research indicates that DMPA users whose weight increased by 5% within the first six months of use are at risk of continued, excessive weight gain. -
Coitus interruptus: Is it rare among teens?
With the wide array of birth control options available today, are adolescents still relying on coitus interruptus? Results of a 2009 study indicate that clinicians should not consider use of contraceptive withdrawal infrequent among teens. -
Check treatment options for bacterial vaginosis
After taking the necessary diagnostic steps, the results are clear: The patient sitting in front of you needs to be treated for bacterial vaginosis (BV). The most common vaginal infection in women of childbearing age, women with BV may present with a white or gray discharge, odor, pain, or burning during urination. Symptoms aren't always present, though. More than 50% of women with BV may be asymptomatic. -
More women delay births — What are their options?
A healthy, nonsmoking woman, age 36, waits in your examination room. While she has been married for seven years, she and her husband are not yet ready to begin their family. What contraceptive choices are available to her? -
Guest Column: Encourage condoms, with passion, please
The HIV community has been asking since 1982: "How might we go about encouraging condom use in discordant couples?" On the whole, our efforts have been a disappointing failure. -
Programs address HPV insurance coverage
Two new programs have been announced by Merck & Co. to help confirm patients' insurance coverage and address providers' reimbursement concerns regarding Gardasil, the quadrivalent human papillomavirus (HPV) vaccine. -
Check new STD testing guidance issued by CDC
If your facility provides comprehensive sexually transmitted disease care for men who have sex with men (MSM), be sure to incorporate new guidance from the Centers for Disease Control and Prevention (CDC) regarding gonorrhea and chlamydia testing.